Clinical studies with chemokine receptor-5 (CCR5)-inhibitors

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 456-462

  Boesecke, Christoph ^a   Pett, Sarah L ^b,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

CCR5; chemokine; co receptor; HIV; maraviroc

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 MONOCLONAL ANTIBODY; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; MARAVIROC; MONOCLONAL ANTIBODY; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; DNA SEQUENCE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; INTESTINE LYMPHATIC TISSUE; LIVER FIBROSIS; MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TISSUE PRESERVATION; VIRAL TROPISM; VIREMIA;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COINFECTION; CYCLOHEXANES; HEPATITIS C, CHRONIC; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RECEPTORS, CCR5; TRIAZOLES; VIRAL TROPISM; VIROLOGY;

EID: 84865632808     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356e933     Document Type: Review

References (57)

1. Cocchi F, deVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1, and MIP-1 as the major HIV-suppressive factors produced by CD8 T cells. Science 1995; 270:1811-1815;
2. Paxton WA, Kang S, Koup RA. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression. AIDS Res Hum Retroviruses 1998; 14(Suppl 1): S89-S92.
3. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1infection. Cell 1996; 86:367-377.
4. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
5. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 30A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-795.
6. Marmor M, Sheppard HW, Donnell D, et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001; 27:472-481.
7. aidsmeds.com/articles/hiv-vicriviroc-merck-1667-18742.shtm [Accessed on 1st May 2012].
8. Lalezari J, Gathe J, Brinson C, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr 2011; 57:118-125.
9. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40.
10. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-269.
11. .Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-155. Excellent review of our current thinking regarding the interaction between inflammation and ageing and their impact on morbidity and mortality in the era of potent cART.
12. Mocroft A, Reiss P, Gasiorowski J, et al. EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-270.
13. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
14. .Fleishaker DL, Garcia Meijide JA, Petrov A, et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebocontrolled trial. Arthritis Res Ther 2012; 14:R11.
15. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866- 872.
16. Cooper DA, Heera J, Goodrich J, et al. for the MERIT Study Team. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naíve subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803-813.
17. http://www.trofileassay.com [Accessed on 1st May 2012].
18. http://www.nhlbi.nih.gov/about/ncep/index.htm [Accessed on 1st May 2012].
19. http://www.fda.gov [Accessed on 2 May 2012].
20. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf [Accessed on 1st May 2012].
21. Gulick RM, Lalezari J, Goodrich J, et al. MOTIVATE Study Teams. Maravirocfor previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
22. Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM. The relationship of CCR5 antagonists to CD4 T-cell gain: A meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials 2010; 11:351- 358.
23. Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: A systematic review and meta-analysis of recent randomized controlled trials. HIV Med 2012; 13:148-155. An interesting insight into the controversy regarding whether use of MVC does lead to enhanced immune restoration.
24. van Kuijk AW, Vergunst CE, Gerlag DM, et al. CCR5 blockade in rheumatoid arthritis: A randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2010; 69:2013-2016.
25. Gerlag DM, Hollis S, Layton M, et al. ESCAPE Study Group. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum 2010; 62:3154- 3160.
26. Price P, Murdoch DM, Agarwal U, et al. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009; 22:651- 663.
27. www.clinical.trials.gov - ClinicalTrials.gov identifier: NCT00988780. [Accessed on 3rd May 2012]
28. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4 T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-11717.
29. Brenchley JM Price DA Schacker TW et al. Microbial translocation is Cause Of Systemic Immune Activation In Chronic HIV Infection. Nature Med 2006; 121365-1371.
30. www.clinical.trials.gov ClinicalTrials.gov Identifier: NCT00525733. [Accessed on 3rd May 2012]
31. Teresa E, Mehandru S, Poles M, et al. antiviral and immunological effects of intensification of suppressive art with maraviroc, a CCR5 Antagonist. Paper #283, 17th CROI, San Francisco, USA, 2010 February 16-19.
32. Wilkin T, Lalama C, Tenorio A, et al. Maraviroc intensification for suboptimal CD4 cell response despite sustained virologic suppression: ACTG 5256. Paper #285, 17th CROI, San Francisco, USA, 2010 February 16-19.
33. Hunt P, Shulman N, Hayes T, et al. Immunomodulatory Effects of MVC Intensification in HIV-infected Individuals with Incomplete CD4 T Cell Recovery during Suppressive ART. Paper 153LB; 18th CROI, Boston, Mass, USA, 2011 February 27-March 2.
34. http://www.ema.europa.eu. Summary of Product Characteristics last updated on the eMC [Accessed on 15 December 2011].
35. Abel S, Davis JD, Ridgway CE, et al. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment. Antivir Ther 2009; 14:831-837.
36. Lazzarin A, Than S, Valluri SR, et al. Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program. HIV Clin Trials 2012; 13:83-89.
37. Macías J, Viloria MM, Rivero A, et al. on behalf of the FIBROCEL study group. Lack of short-term increase in serum mediators of fibrogenesis and in noninvasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2012. Important first data on the potential role of maraviroc as an adjunctive antifibrotic agent in those with HCV-HIV coinfection.
38. Nasta P, Gatti F, Borghi F, et al. Liver Stiffness (LS) change in HIV-Hepatitis C (HCV) coinfected patients treated with CCR5 inhibitor based antiretroviral therapy. Abstract H3-810 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Il, USA. September 17-20, 2011.
39. www.clinical.trials.gov ClinicalTrials.gov identifier NCT01327547. [Accessed on 3rd May 2012]
40. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
41. Poveda E, Alcamí J, Paredes R, et al. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010; 12:135-148.
42. ClinicalTrials.gov identifier: NCT00827112. [Accessed on 1st May 2012]
43. Portsmouth S, Craig C, Mills A, et al. 48-week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with ritonavirboosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) ATV/r in treatment-naíve (TN) patients infected with CCR5-tropic HIV-1 (Study A4001078). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome. Abstract TUAB0103.
44. www.clinical.trials.gov ClinicalTrials.gov Identifier NCT01345630. [Accessed on 3rd May 2012]
45. http://www.daignet.de/site-content/hiv-therapie/leitlinien-1. [Accessed on3rd May 2012]
46. Vandekerckhove L, Wensing A, Kaiser R, et al. on behalf of the European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet InfectDis 2011.An important review of tropism testing methodology and clinical outcomes withCCR5-blockers.
47. Obermeier MJ, Carganico A, Dupke S, et al. Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort. J Int AIDS Soc 2010; 13(Suppl 4):129.
48. www.clinical.trials.gov ClinicalTrials.gov Identifier: NCT01384682. [Accessedon 1st May 2012]
49. Spudich SS, Huang W, Nilsson AC, et al. HIV-1 chemokine coreceptorutilization in paired cerebrospinal fluid and plasma. J Infect Dis 2005;191:890-898.
50. Soulié C, Tubiana R, Simon A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr 2009; 51:60-64.
51. Walker DK, Bowers SJ, Mitchell RJ, et al. Preclinical assessment ofthe distribution of maraviroc to potential human immunodeficiencyvirus (HIV) sanctuary sites in the central nervous system (CNS) andgut-associated lymphoid tissue (GALT). Xenobiotica 2008; 38:1330- 1339.
52. Tiraboschi JM, Niubo J, Curto J, Podzamczer D. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 55:606-609.
53. Garvey L, Nelson M, Latch N, et al. CNS effects of a CCR5 inhibitor in HIV-infected subjects: A pharmacokinetic and cerebral metabolite study.J Antimicrob Chemother 2012; 67:206-212. First data on the potential clinical utility of MVC intensification in improvingsubclinical neuronal disease in HIV.
54. www.clinical.trials.gov ClinicalTrials.gov Identifier: NCT00624195.
55. Jacobson JM, Lalezari JP, Thompson MA, et al. Phase 2a study of theCCR5monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Antimicrob Agents Chemother 2010; 54:4137-4142; Epub 2010 Jul 26.
56. JM Jacobson, MA Thompson, JP Lalezari, et al. Anti-HIV-1 activity of weeklyor biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonalantibody. J Infect Dis 2010; 201:1481-1487.
57. www.clinical.trials.gov ClinicalTrials.gov Identifier: NCT01272258. [Accessedon 3rd May 2012]